Fig. 2From: Feasibility of a randomized single-blind crossover trial to assess the effects of the second-generation slow-release dopamine agonists pramipexole and ropinirole on cued recall memory in idiopathic mild or moderate Parkinson’s disease without cognitive impairmentCONSORT diagram showing the number of patients assessed for eligibility, randomized, follow-up and complete datasets analysedBack to article page